PTC Therapeutics Past Earnings Performance
Past criteria checks 0/6
PTC Therapeutics's earnings have been declining at an average annual rate of -22.6%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been growing at an average rate of 26.3% per year.
Key information
-22.6%
Earnings growth rate
-16.7%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 26.3% |
| Return on equity | n/a |
| Net Margin | -66.8% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
PTC Therapeutics, Inc. (NASDAQ:PTCT) Surges 27% Yet Its Low P/S Is No Reason For Excitement
Mar 03
PTC Therapeutics: Already Generates Revenues, But Lots Of Outstanding Options
Feb 11An Intrinsic Calculation For PTC Therapeutics, Inc. (NASDAQ:PTCT) Suggests It's 49% Undervalued
Jun 23Benign Growth For PTC Therapeutics, Inc. (NASDAQ:PTCT) Underpins Its Share Price
May 18An Intrinsic Calculation For PTC Therapeutics, Inc. (NASDAQ:PTCT) Suggests It's 49% Undervalued
Mar 02PTC pauses enrollment in mid-stage study for Huntington's disease candidate in U.S.
Oct 19PTC Therapeutics betas topline expectations, strengthens commercial portfolio
Aug 05PTC Therapeutics gene therapy Upstaza wins approval in EU for ultra-rare neuromuscular disorder
Jul 20PTC Therapeutics: DMD Trial News Unlikely To Restore Flagging Share Price
Jun 24Are PTC Therapeutics, Inc. (NASDAQ:PTCT) Investors Paying Above The Intrinsic Value?
May 27PTC Therapeutics: One Of The Leaders In The Treatment Of Rare Diseases
Apr 11Is Therapeutics (NASDAQ:PTCT) Using Debt Sensibly?
Feb 09PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Could Be 35% Below Their Intrinsic Value Estimate
Dec 27Revenue & Expenses BreakdownBeta
How PTC Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 938 | -627 | 333 | 0 |
| 30 Sep 23 | 798 | -642 | 349 | 0 |
| 30 Jun 23 | 819 | -618 | 348 | 0 |
| 31 Mar 23 | 770 | -571 | 340 | 0 |
| 31 Dec 22 | 699 | -559 | 326 | 0 |
| 30 Sep 22 | 697 | -531 | 320 | 0 |
| 30 Jun 22 | 618 | -556 | 309 | 0 |
| 31 Mar 22 | 569 | -522 | 298 | 0 |
| 31 Dec 21 | 539 | -524 | 286 | 0 |
| 30 Sep 21 | 492 | -455 | 274 | 0 |
| 30 Jun 21 | 472 | -391 | 263 | 0 |
| 31 Mar 21 | 430 | -454 | 247 | 0 |
| 31 Dec 20 | 381 | -438 | 244 | 0 |
| 30 Sep 20 | 358 | -441 | 233 | 0 |
| 30 Jun 20 | 311 | -432 | 225 | 0 |
| 31 Mar 20 | 322 | -292 | 220 | 0 |
| 31 Dec 19 | 307 | -252 | 203 | 0 |
| 30 Sep 19 | 297 | -222 | 188 | 0 |
| 30 Jun 19 | 279 | -213 | 175 | 0 |
| 31 Mar 19 | 262 | -181 | 159 | 0 |
| 31 Dec 18 | 265 | -128 | 152 | 0 |
| 30 Sep 18 | 256 | -78 | 139 | 0 |
| 30 Jun 18 | 245 | -61 | 133 | 0 |
| 31 Mar 18 | 224 | -69 | 129 | 0 |
| 31 Dec 17 | 194 | -79 | 121 | 0 |
| 30 Sep 17 | 142 | -107 | 108 | 0 |
| 30 Jun 17 | 123 | -108 | 101 | 0 |
| 31 Mar 17 | 90 | -130 | 95 | 0 |
| 31 Dec 16 | 83 | -142 | 97 | 0 |
| 30 Sep 16 | 70 | -166 | 99 | 0 |
| 30 Jun 16 | 57 | -174 | 97 | 0 |
| 31 Mar 16 | 48 | -174 | 90 | 0 |
| 31 Dec 15 | 37 | -170 | 82 | 0 |
| 30 Sep 15 | 37 | -147 | 74 | 0 |
| 30 Jun 15 | 29 | -131 | 63 | 0 |
| 31 Mar 15 | 24 | -118 | 55 | 0 |
| 31 Dec 14 | 25 | -94 | 45 | 0 |
| 30 Sep 14 | 17 | -84 | 34 | 0 |
| 30 Jun 14 | 32 | -62 | 30 | 0 |
| 31 Mar 14 | 37 | -51 | 28 | 0 |
| 31 Dec 13 | 35 | -66 | 25 | 0 |
| 30 Sep 13 | 37 | -48 | 21 | 0 |
| 30 Jun 13 | 28 | -51 | 18 | 0 |
Quality Earnings: PTCT is currently unprofitable.
Growing Profit Margin: PTCT is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PTCT is unprofitable, and losses have increased over the past 5 years at a rate of 22.6% per year.
Accelerating Growth: Unable to compare PTCT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PTCT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Return on Equity
High ROE: PTCT's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.